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To the Editor:
The PI3Kδ inhibitor idelalisib is approved for the treatment
of relapsed or refractory (R/R) follicular lymphoma (FL)
[1, 2]. However, the duration of response is mostly limited,
especially in patients who do not achieve a complete
response (CR). A median progression-free survival (PFS) of
only 11 months was reported in patients in partial remission
(PR) compared with 30.6 months in patients in CR [2].
Therefore, effective consolidation will be necessary to
achieve long-term remissions. Allogeneic stem cell trans-
plantation (alloSCT) is an option in patients responding to
idelalisib [3, 4], though there is limited information on the
impact of previous exposure to idelalisib on the feasibility
and safety of alloSCT. This is of particular importance as
immune-mediated toxicities of idelalisib including hepatitis,
colitis, pneumonitis, and skin rash, probably mediated by
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selective inhibition of regulatory T cells, may interfere with
a subsequent allogeneic stem cell transplant [5, 6].
The aim of this European Society for Blood and Marrow
Transplantation (EBMT) registry study (study code LWP
2013-N-03) was to assess the safety and efficacy of alloSCT
after prior exposure to idelalisib in patients with FL.
Patients aged ≥ 18 years who underwent a first alloSCT for
FL after exposure to idelalisib at any time before transplant
between 2015 and 2018 and who were registered with the
EBMT were eligible for inclusion. Any donor type and any
conditioning regimen were allowed. Baseline patient, dis-
ease, and transplant data were collected from MED-A
forms. Centers were requested to provide additional treat-
ment and follow-up information (MED-B and C forms).
The primary endpoint was nonrelapse mortality (NRM) at 6
and 12 months post alloSCT. Secondary endpoints were
overall survival (OS) and PFS as well as incidence of
relapse (RI), engraftment, and acute or chronic graft-versus-
host disease (GvHD). Informed consent for transplantation
and data collection was obtained locally according to the
regulations applicable at the time of transplantation. All
transplant centers have been required to obtain written
informed consent prior to data registration with the EBMT
following the 1964 Helsinki declaration and its later
amendments. Statistical analysis was performed using the
survival and cmprsk packages in R 3.3.2 (R Foundation for
Statistical Computing, Vienna, Austria, http://www.R-
project.org). Survival curves were estimated by the
Kaplan–Meier method. Cumulative incidence taking into
account competing risks were estimated for NRM and RI.
Sixty-three patients met the eligibility criteria. Eighteen
were excluded because of missing follow-up, unclear ide-
lalisib starting date, or unclear exposure to idelalisib, leav-
ing 45 patients for analysis. A total of 33 of these patients
received idelalisib for bridging to alloSCT (as last line
before transplant). Overall, 80% of all patients were in PR
or better at alloSCT, including 20% CRs. In patients who
had received idelalisib for bridging to alloSCT, 82% had
responded to the idelalisib-containing regimen with 15% of
the patients in CR. The median follow-up was 12 months.
Patient characteristics details are shown in Table 1.
The median time to reach neutrophils > 0.5/nl and pla-
telets > 20/nl was 16 days post transplant. Two patients
failed to engraft, both due to early death from infection, 10
and 23 days post alloSCT, respectively. Acute GVHD
(aGvHD) grade 2–4 was observed in 45% and grade 3–4 in
24% of patients. Overall, 35% of evaluable patients-at-risk
developed chronic GvHD (cGvHD), and 10% were classi-
fied as extensive disease. Eleven NRM events were repor-
ted, four within the first month, two at 6 months, and one
each at 3, 7, 10, 16, and 20 months post alloSCT. Causes of
death included GvHD (n= 6), infection (n= 5), relapse
(n= 2), GI toxicity (n= 1), and secondary malignancy
(n= 1). Six- and twelve-month incidences of NRM were 12
and 24% (Fig. 1a), RI were 12 and 12% (Fig. 1b), PFS were
76 and 64% (Fig. 1c), and OS were 84 and 64% (Fig. 1d).
Disease status at transplant (SD/PR versus CR) did not have
an impact on outcome in the current analysis. Outcomes of
patients who received idelalisib directly before alloSCT for
bridging were comparable with the entire cohort.
The outcome observed in this series seems to be com-
parable with that reported in the largest study so far on
alloSCT in FL, where 1567 patients from the Center for
International Blood and Marrow Transplant Research and
the EBMT databases who were not previously exposed to
idelalisib were retrospectively analyzed with 3-year NRM,
RI, PFS, and OS estimates of 25, 17, 58, and 66% (95%
confidence interval 23–27, 15–19, 55–60, and 64–68%) [4].
With a shorter follow-up in the current study, 12-month
outcomes are in line with the findings reported by Sureda
et al. [4] Although grade 2–4 aGvHD in nearly half of our
cohort (45%) seems to be higher compared with the study
Table 1 Patient characteristics.
Patients with follicular lymphoma All (n= 45)
Age at alloSCT, median (range), years 57 (34–71)
Female gender, n (%) 18 (40)
Pretreatments before alloSCT, median (range) 4 (2–8)




PD/primary refractory 6 (13)
Unknown 2 (4)
Good performance status at alloSCT (Karnofsky
90–100%), n (%)
30/42 (71)
Matched related donor n (%) 12 (27)
Conditioning, n (%)
TBI based 13 (29)
Alkylator based 32 (71)
Alemtuzumab 5 (11)
ATG 22 (49)
Reduced intensity conditioninga (RIC), n (%) 31 (69)
Idelalisib administration, n (%)
Monotherapy
Anti-CD20 antibody combination 11 (24)
Chemotherapy combination 2 (4)
AutoSCT prior to alloSCT, n (%) 22 (49)
Median follow-up of survivors, months after
alloSCT (range)
12 (2–35)
alloSCT allogeneic stem cell transplantation, ATG anti-thymoglobulin,
autoSCT autologous stem cell transplantation, CR complete remission,
PD progressive disease, PR partial remission, SD stable disease, TBI
total body irradiation.
aAccording to the EBMT criteria.
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by Sureda et al. that reported 20% aGvHD grade 2–4 [4], it
is in keeping with other registry studies on alloSCT in FL
[7, 8]. In contrast, there were no signs of an increased
incidence of cGvHD after pretransplant idelalisib exposure.
While long-term results of CAR trials are still awaited,
alloSCT remains the only potentially curative treatment
option in advanced stage FL, even though late relapses can
occur [4, 9–11]. AutoSCT may also provide long-term
remissions in chemo-sensitive disease but a significant pro-
portion of patients will eventually relapse [12]. Other specific
pathway inhibitors such as the BTK inhibitor ibrutinib [13] or
the BCL-2 inhibitor venetoclax [14] may be additional
options in R/R FL but are not approved for this indication.
Our results suggest that idelalisib does not increase the risk of
NRM or GVHD when used pre transplant. This has been a
concern since idelalisib has been shown to suppress the
function of regulatory T cells, which may increase the risk of
immunologic complications post alloSCT [15].
In summary, the outcome of patients who received ide-
lalisib before alloSCT was comparable with previous
reports of alloSCT in FL patients without idelalisib pre-
treatment. Idelalisib seems to be an effective and safe drug
for bridging patients with FL to alloSCT, especially in the
chemotherapy-refractory setting, with a high percentage of
patients with responding disease at the time of transplant.
However, further studies are required to confirm that ide-
lalisib bridging does not increase the risk of aGvHD.
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Fig. 1 Outcome of follicular lymphoma patients after allogeneic
stem cell transplantation. Nonrelapse mortality (NRM; a), incidence
of relapse (RI; b), progression-free survival (PFS; c), and overall
survival (OS; d) for patients with idelalisib exposure before allogeneic
stem cell transplantation (alloSCT).
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